124 related articles for article (PubMed ID: 8625078)
1. Application of quantitative analysis to biologic profile evaluation in breast cancer.
Querzoli P; Ferretti S; Albonico G; Magri E; Scapoli D; Indelli M; Nenci I
Cancer; 1995 Dec; 76(12):2510-7. PubMed ID: 8625078
[TBL] [Abstract][Full Text] [Related]
2. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
4. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression.
Querzoli P; Albonico G; Ferretti S; Rinaldi R; Beccati D; Corcione S; Indelli M; Nenci I
Cancer; 1998 Jul; 83(1):89-97. PubMed ID: 9655297
[TBL] [Abstract][Full Text] [Related]
5. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
6. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
7. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
[TBL] [Abstract][Full Text] [Related]
8. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
Chu JS; Lee WJ; Chen KM; Hsu HC
J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
[TBL] [Abstract][Full Text] [Related]
10. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
11. Association between hormone receptors and HER-2/neu is age-related.
Wang B; Wang X; Zou Y
Int J Clin Exp Pathol; 2015; 8(7):8472-9. PubMed ID: 26339420
[TBL] [Abstract][Full Text] [Related]
12. SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS.
Villa NM; Li N; Yeh MW; Hurvitz SA; Dawson NA; Leung AM
Endocr Pract; 2015 Sep; 21(9):1040-5. PubMed ID: 26121443
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics.
Slobodova Z; Ehrmann J; Krejci V; Zapletalova J; Melichar B
Neoplasma; 2011; 58(3):189-97. PubMed ID: 21391734
[TBL] [Abstract][Full Text] [Related]
14. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
18. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
20. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
